The Edinburgh based smart home security start up secured £1.7m from angel investors and a construction firm.
"It became very clear from my discussions with investors over recent months that they like the space Boundary is operating in. We have worked hard to get to grips with the stringent regulatory framework that exists around the police response intruder alarm market and this is clearly a key strength of the Boundary model."
The Imperial College spin-out has secured seed backing led by IQ Capital to scale its team and customer base.
"We are delighted to receive this funding from our investor partners – it’s a fantastic indication of their faith in the commercial applications of our technology. This funding will give TOffeeAM the opportunity to continue our success at speeding up 3D printing across all industries by up to 20 times faster and to expand our team with expert engineers and other team members, and continue to scale the solution to serve our rapidly expanding customer base. We are at the beginning of an exciting journey, and this funding will help drive our growth and the wider use of this transformative technology across a variety of industries."
Draper Esprit led the Series C financing, with continued backing from Amadeus Capital Partners, BlackFin Tech, and Passion Capital.
"We have been very busy in the two years since our last funding round in 2018. Our approach to tackling fraud and risk for enterprise-scale businesses has resonated with the market and we’ve grown our client base rapidly"
The Oxford startup raised the capital from Microsoft's venture fund and Mayfield following its success in the Female Founders Competition.
"We are so excited to name iLoF a winner of the Female Founders Competition and invest $1 million alongside Mayfield. iLoF’s technology promises to create effective treatments tailored for the individual, which will change healthcare trajectories for millions of people living with complex disorders. Their mission is humbling, and we are thrilled to support this company with our investment and as a board observer."
Par Equity led the Series A round to support technology development and commercial expansion.
"We are delighted to continue working with Par Equity who have been very supportive of our company and our vision. This investment will enable us to continue to develop and commercialise our cutting-edge technology that addresses a major unmet need in the development of novel therapies that can significantly reduce costs of care and improve patient outcomes for millions of people worldwide."